- In September 2023, Pfizer and BioNTech gained FDA approval for their supplemental Biologics License Application, allowing use of their COMIRNATY 2023-2024 Formulation for ages 12 and up, with emergency authorization for children aged 6 months to 11 years against the Omicron XBB.1.5 variant. The current recommendation suggests a single dose for most individuals aged 5 and above, with potential for additional doses for under 5s lacking a complete three-dose series with earlier COVID-19 vaccines
- In February 2025, a study published in the American Journal of Obstetrics & Gynecology found that funisitis significantly increases the risk of death or cerebral palsy in extremely preterm infants born before 27 weeks of gestation. Among survivors, exposure to funisitis was associated with a 23% higher risk of cerebral palsy, with approximately 60% of this risk attributed directly to funisitis itself and 40% mediated through preterm birth. The findings underscore the importance of early detection and intervention strategies for intrauterine inflammation to improve neonatal outcomes
